Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · IEX Real-Time Price · USD
14.00
-0.32 (-2.23%)
Jul 2, 2024, 4:00 PM EDT - Market closed

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current202320222021
Market Capitalization
520504425534
Market Cap Growth
-0.73%18.58%-20.54%-
Enterprise Value
255216258243
PE Ratio
21.88-75.32-4.49-10.44
PS Ratio
3.193.90--
PB Ratio
1.932.082.001.79
P/FCF Ratio
-5.073.75-4.39-9.64
P/OCF Ratio
-5.343.60-4.53-10.51
EV/Sales Ratio
1.561.67--
EV/EBITDA Ratio
5.8314.49-2.78-4.86
EV/EBIT Ratio
6.2917.90-2.73-4.75
EV/FCF Ratio
-2.251.61-2.67-4.39
Debt / Equity Ratio
0.250.280.12-
Debt / EBITDA Ratio
1.524.58-0.28-
Debt / FCF Ratio
-0.710.51-0.27-
Quick Ratio
2.352.288.7743.32
Current Ratio
2.382.339.5544.46
Asset Turnover
0.330.2700
Return on Equity (ROE)
9.70%-2.90%-38.70%-39.80%
Return on Assets (ROA)
4.80%-1.40%-33.20%-29.30%
Return on Capital (ROIC)
4.10%0.56%-40.78%-17.12%
Earnings Yield
4.52%-1.33%-22.28%-9.57%
FCF Yield
-18.07%26.65%-22.77%-10.38%
Buyback Yield / Dilution
-7.46%-5.61%-399.27%-467.09%
Total Shareholder Return
-7.46%-5.61%-399.27%-467.09%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).